Logo image of KRON

KRONOS BIO INC (KRON) Stock Fundamental Analysis

NASDAQ:KRON - Nasdaq - US50107A1043 - Common Stock - Currency: USD

0.88  +0.01 (+1.49%)

Fundamental Rating

3

Overall KRON gets a fundamental rating of 3 out of 10. We evaluated KRON against 551 industry peers in the Biotechnology industry. KRON has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, KRON is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year KRON has reported negative net income.
In the past year KRON has reported a negative cash flow from operations.
In the past 5 years KRON always reported negative net income.
In the past 5 years KRON always reported negative operating cash flow.
KRON Yearly Net Income VS EBIT VS OCF VS FCFKRON Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

KRON's Return On Assets of -59.63% is in line compared to the rest of the industry. KRON outperforms 41.76% of its industry peers.
KRON has a Return On Equity (-80.80%) which is in line with its industry peers.
Industry RankSector Rank
ROA -59.63%
ROE -80.8%
ROIC N/A
ROA(3y)-55.74%
ROA(5y)-44.62%
ROE(3y)-74.53%
ROE(5y)-57.27%
ROIC(3y)N/A
ROIC(5y)N/A
KRON Yearly ROA, ROE, ROICKRON Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

KRON does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KRON Yearly Profit, Operating, Gross MarginsKRON Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

More info and screens

7

2. Health

2.1 Basic Checks

KRON does not have a ROIC to compare to the WACC, probably because it is not profitable.
KRON has more shares outstanding than it did 1 year ago.
The number of shares outstanding for KRON has been increased compared to 5 years ago.
KRON has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
KRON Yearly Shares OutstandingKRON Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
KRON Yearly Total Debt VS Total AssetsKRON Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -7.09, we must say that KRON is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -7.09, KRON is doing worse than 67.74% of the companies in the same industry.
KRON has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -7.09
ROIC/WACCN/A
WACC8.93%
KRON Yearly LT Debt VS Equity VS FCFKRON Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

KRON has a Current Ratio of 12.93. This indicates that KRON is financially healthy and has no problem in meeting its short term obligations.
KRON has a Current ratio of 12.93. This is amongst the best in the industry. KRON outperforms 84.77% of its industry peers.
KRON has a Quick Ratio of 12.93. This indicates that KRON is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 12.93, KRON belongs to the best of the industry, outperforming 84.77% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 12.93
Quick Ratio 12.93
KRON Yearly Current Assets VS Current LiabilitesKRON Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 46.50% over the past year.
Looking at the last year, KRON shows a very strong growth in Revenue. The Revenue has grown by 21.17%.
EPS 1Y (TTM)46.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.66%
Revenue 1Y (TTM)21.17%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-26.03%

3.2 Future

The Earnings Per Share is expected to decrease by -1.90% on average over the next years.
The Revenue is expected to grow by 47.58% on average over the next years. This is a very strong growth
EPS Next Y0%
EPS Next 2Y-1.9%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y14.47%
Revenue Next 5Y47.58%

3.3 Evolution

KRON Yearly Revenue VS EstimatesKRON Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2027 2028 2029 2030 2031 20M 40M 60M 80M 100M
KRON Yearly EPS VS EstimatesKRON Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

KRON reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KRON. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KRON Price Earnings VS Forward Price EarningsKRON Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KRON Per share dataKRON EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.9%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for KRON!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KRONOS BIO INC

NASDAQ:KRON (6/20/2025, 8:00:02 PM)

0.88

+0.01 (+1.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-06 2025-08-06/amc
Inst Owners29.29%
Inst Owner Change-33.01%
Ins Owners6.07%
Ins Owner Change-4.88%
Market Cap53.65M
Analysts82.86
Price Target2.3 (161.36%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)18.34%
Min Revenue beat(2)-9.53%
Max Revenue beat(2)46.2%
Revenue beat(4)3
Avg Revenue beat(4)30.02%
Min Revenue beat(4)-9.53%
Max Revenue beat(4)72.75%
Revenue beat(8)6
Avg Revenue beat(8)35.99%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.84
P/FCF N/A
P/OCF N/A
P/B 0.67
P/tB 0.67
EV/EBITDA N/A
EPS(TTM)-1.07
EYN/A
EPS(NY)-1.38
Fwd EYN/A
FCF(TTM)-0.89
FCFYN/A
OCF(TTM)-0.89
OCFYN/A
SpS0.15
BVpS1.31
TBVpS1.31
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -59.63%
ROE -80.8%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-55.74%
ROA(5y)-44.62%
ROE(3y)-74.53%
ROE(5y)-57.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.21%
Cap/Sales 0.03%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.93
Quick Ratio 12.93
Altman-Z -7.09
F-Score6
WACC8.93%
ROIC/WACCN/A
Cap/Depr(3y)19.19%
Cap/Depr(5y)282.4%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)46.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.66%
EPS Next Y0%
EPS Next 2Y-1.9%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)21.17%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-26.03%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y14.47%
Revenue Next 5Y47.58%
EBIT growth 1Y53.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-7.02%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y26.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y25.92%
OCF growth 3YN/A
OCF growth 5YN/A